GlobeNewswire EN Nachrichten

 

Highlights...

VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Rio2 Limited (“Rio2” or the “Company”) (TSX: RIO; OTCQX: RIOFF; BVL: RIO) is pleased to announce that due to strong investor demand, the Company, Raymond James Ltd., (“Raymond James”), Stifel Nicolaus Canada Inc. (“Stifel”), and BMO Nesbitt Burns Inc. (“BMO”), the co-lead underwriters and joint bookrunners (collectively, the “Underwriters”) have upsized the previously announced “bought deal” financing from C$140 million to approximately C$166 million, or approximately US$120 million (the “Equity Financing”). Under the Equity Financing, the Underwriters have agreed to purchase, on a “bought deal” basis, 74,865,000 Subscription Receipts of the Company (“Subscription Receipts”) at a price of $2.22 per Subscription Receipts (the “Issue Price”) for gross proceeds of C$166,200,300....

The study of mesutoclax in the treatment of r/r MCL was selected for oral presentation, while the CLL/SLL and AML studies were chosen for poster....

VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") announced today it will report its financial results for the fourth quarter and the year ended September 30, 2025 on Monday, December 15, 2025 before the market opens. The financial statements and MD&A will be available on SEDAR at www.sedarplus.ca and on the Company's website....

TORONTO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cygnus Metals Limited (“Cygnus” or the “Company”) advises that it issued an aggregate of 202,500 performance rights (“Performance Rights”) to employees on 27 November 2025 under the Company's Omnibus Equity Incentive Plan (“Plan”)....

BOSTON, MA, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Netcapital Inc. (Nasdaq: NCPL, NCPLW) (the “Company”), a digital private capital markets ecosystem, announced today the grant of an inducement restricted stock award of 1,000,000 shares of common stock (“Restricted Stock Award”) to a new employee under the Netcapital Inc. 2023 Omnibus Equity Incentive Plan (the “Plan”). The Restricted Stock Award was granted as an inducement under the Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4)....

VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) (“Monument” or the “Company”) is pleased to announce the results from its Annual General Meeting of shareholders (the “AGM”) held on December 08, 2025, in Vancouver, B.C....

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION TO THE UNITED STATES...

ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it presented four year follow-up data from its randomized controlled, registrational Phase II study of Olverembatinib in patients with tyrosine kinase inhibitor (TKI)-resistant/intolerant chronic-phase chronic myeloid leukemia (CML-CP), in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting, being held in Orlando, Florida. Building on results released in an oral presentation at ASH 2023, these data reaffirm Olverembatinib's differentiated long-term efficacy and safety....

ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has presented the first dataset from the global registrational Phase III study (POLARIS-1) of the company's novel, investigational drug, Olverembatinib (HQP1351), in combination with low-intensity chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting, being held in Orlando, Florida....

ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has presented the latest data on Olverembatinib, the Company's novel drug, in second-line treatment of patients with chronic myeloid leukemia (CML) in chronic-phase (-CP), in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting, being held in Orlando, Florida. This presentation provided an update on the results released in an oral presentation at ASH 2024 and featured data from a longer follow-up on efficacy and safety....

RetinalGenix signs agreement to hire M. Cory Zwerling as its chief financial officer and interim chief operating officer, effective January 1, 2026...

STAMFORD, Conn., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Star Group, L.P. (the "Company" or "Star") (NYSE:SGU), a home energy distributor and services provider, today announced financial results for its fiscal 2025 full year and fourth quarter, the three months ended September 30, 2025....

Return Marks Full-Circle Moment for Scenebot Stage Discovery Return Marks Full-Circle Moment for Scenebot Stage Discovery...

TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that anti-Aβ protofibril* antibody “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), has been included in the “Commercial Insurance Innovative Drug List” (Chinese: 商业健康保险创新药品目录), recently introduced by the National Healthcare Security Administration (NHSA) of China. The inclusion of LEQEMBI in this list marks a meaningful step toward expanding access to early Alzheimer's Disease (AD) treatment in China....

SecureTech Backing Enables AI UltraProd's U.S. Accessory Dwelling Unit Beachhead; 2026 Rollout and Expansion Strategy...

STEINHAUSEN, Switzerland, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Transocean Ltd. (NYSE: RIG) (“Transocean”) today announced the execution of a six-well contract in Australia with an undisclosed operator for the Deepwater Skyros. The estimated 320-day campaign is expected to commence in the first quarter of 2027 and contribute approximately $130 million in backlog, excluding compensation for mobilization and demobilization. The award includes priced options that, if fully exercised, could keep the drillship working in Australia into early 2030....

VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Mawson Finland Limited (“Mawson” or the “Company”) (TSX-V: MFL) is pleased to announce that the Ontario Superior Court of Justice (Commercial List) has granted the final order (the "Final Order") in connection with the proposed business combination of Mawson and First Nordic Metals Corp. (TSX-V: FNM, FNSE: FNMC SDB, OTCQX: FNMCF, FRA: HEG0) (“First Nordic”), pursuant to which it is proposed that First Nordic will acquire all of the outstanding common shares of Mawson by way of a plan of arrangement (the “Arrangement”), pursuant to the terms and subject to the conditions of the arrangement agreement between Mawson and First Nordic dated September 14, 2025. As previously announced, the Arrangement was overwhelmingly approved by Mawson's shareholders at a special meeting held on December 4, 2025 (the "Meeting")...

HERZLIYA, Israel, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX) (the “Company”) announced today, further to its announcement of December 7, 2025, that the Company completed in Israel a tender to qualified investors as defined under the Israeli Securities Law, 1968 (“Qualified Investors”) of notes, by expanding its Series A Notes, and Series 1 Warrants (the “Notes” and the “Warrants”, respectively and together, the “Securities”)....

BURNABY, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- INTERFOR CORPORATION (“Interfor” or the “Company”) (TSX: IFP) announced today that it has made several leadership changes. Mike Mackay has been appointed Executive Vice President & Chief Financial Officer, effective December 8, 2025. Mr. Mackay, who joined Interfor in 2015, has held several leadership roles in the Company's finance organization, most recently serving as Vice President, Corporate Development & Treasury. Mr. Mackay will succeed Rick Pozzebon, who will be leaving Interfor to pursue other opportunities....